Effects and Safety of FGF21 Analogs on Glycemic Parameters, Lipid Profiles, and Adiponectin in Overweight and Obese Adults: A Meta-Analysis of Randomized Controlled Trials.

ABSTRACT: Objective: Fibroblast growth factor 21 (FGF21) analogs have been used to improve glucose homeostasis and lipid metabolism; however, their effects remain contentious. The present meta-analysis aimed to review the effects and safety of FGF21 analogs on glycemic parameters, lipid profiles, and adiponectin (ADP) levels in overweight or obese adults. Methods: A systematic literature search for randomized controlled trials (RCTs) was conducted up to June 2025. A random-effects model or a common-effect model was used to calculate the mean difference (MD) or standardized MD (SMD), along with the corresponding 95% confidence intervals (CIs). Results: This meta-analysis including 11 RCTs showed that FGF21 analogs reduced triglycerides (MD = -59.33 mg/dL, 95% CI = -84.61 to -34.0

SUBMITTER: Nie Z 

PROVIDER: S-EPMC12316501 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature